An open-label study investigating the efficacy and safety of 12 - 96 weeks of telmisartan treatment in patients with hypertension

Journal of International Medical Research

Volumn 31, Issue 6, 2003, Pages 561-574

  Ingino, C ^a   Farsang, C ^b   Laucevicius, A ^c   Bergovec, M ^d  

^a HOSPITAL MILITAR CENTRAL   (Argentina)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c Private Medical Centre   (Lithuania)

^d University of Zagreb School of Medicine   (Croatia)

Author keywords

Angiotensin II receptor blocker; Blood pressure control; Hypertension; Telmisartan

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; HYDROCHLOROTHIAZIDE; TELMISARTAN;

ADULT; AGED; ARTICLE; BONE PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FATIGUE; FEMALE; GEOGRAPHIC DISTRIBUTION; HEADACHE; HEART INFARCTION; HUMAN; HYPOTENSION; JAUNDICE; MAJOR CLINICAL STUDY; MALAISE; MALE; MONOTHERAPY; MULTICENTER STUDY; MYALGIA; OPEN STUDY; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

EID: 0346888591     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000303100613     Document Type: Article

References (39)

1. Meredith PA: Organ protection and optimal blood pressure control. Am J Hypertens 1995; 8: 59S-62S.
2. Hansson L: The benefits of lowering elevated blood pressure: a critical review of studies of cardiovascular morbidity and mortality in hypertension. J Hypertens 1996; 14: 537-544.
3. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al: Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765-774.
4. Unger T, Culman J, Gohlke P: Angiotensin II receptor blockade and end-organ protection: pharmacological rationale and evidence. J Hypertens 1998; 16 (Suppl): S3-S9.
5. Strawn WB, Dean RH, Ferrario CM: Novel mechanisms linking angiotensin II and early atherogenesis. J Renin Angiotensin Aldosterone Syst 2000; 1: 11-17.
6. 2-receptors: conceptual and clinical effects. J Renin Angiotensin Aldosterone Syst 2000; 1 (Suppl 2 ): 6-9.
7. Lucius R, Gallinat S, Busche S, Rosenstiel P, Unger T: Beyond blood pressure: new roles for angiotensin II. Cell Mol Life Sci 1999; 56: 1008-1019.
8. Israili ZH, Hall WD: Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117: 234-242.
9. Ravid D, Lishner M, Lang R, Ravid M: Angiotensin-converting enzyme inhibitors and cough: a prospective evaluation in hypertension and in congestive heart failure. J Clin Pharmacol 1994; 34: 1116-1120.
10. Chung O, Unger T: Angiotensin II receptor blockade and end-organ protection. Am J Hypertens 1999; 12: 150S-156S.
11. 2 receptors. Blood Press 1996; 5 (Suppl): 47-52.
12. 2 angiotensin receptors. In: Hypertension: A Companion to Brenner and Rector's The Kidney (Oparil S, Weber MA, eds). Philadelphia: WB Saunders, 2000; pp100-110.
13. Mazzolai L, Burnier M: Comparative safety and tolerability of angiotensin II receptor antagonists. Drug Saf 1999; 21: 23-33.
14. Smith DHG, Neutel JM, Morgenstern P: Once-daily telmisartan compared with enalapril in the treatment of hypertension. Adv Ther 1998; 15: 229-240.
15. 1, receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998; 15: 206-217.
16. Neutel JM, Frishman WH, Oparil S, Papademitriou V, Guthrie G: Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am J Ther 1999; 6: 161-166.
17. Lacourcière Y: The incidence of cough: a comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist. Telmisartan Cough Study Group. Int J Clin Pract 1999; 53: 99-103.
18. Sharpe M, Jarvis B, Goa KL: Telmisartan: a review of its use in hypertension. Drugs 2001; 61: 1501-1529.
19. Freytag F, Holwerda NJ, Karlberg BE, Meinicke TW, Schumacher H: Long-term exposure to telmisartan as monotherapy or combination therapy: efficacy and safety. Blood Press 2002; 11: 173-181.
20. Neutel JM, Klein C, Meinicke TW, Schumacher H: Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications. Blood Press 2002; 11: 302-309.
21. Lacourcière Y, Lenis J, Orchard R, Lewanczuk R, Houde M, Pesant Y, et al: A comparison of the efficacy and duration of action of the angiotensin II receptor blocker telmisartan to amlodipine. Blood Press Monit 1998; 3: 295-302.
22. 1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. J Hypertens 1999; 17: 293-302.
23. Mallion JM, Siché JP, Lacourcière Y: ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13: 657-664.
24. Littlejohn T, Mroczek W, Marbury T, VanderMaelen CP, Dubiel RF: A prospective, randomized, open-label trial comparing telmisartan 80 mg and valsartan 80 mg in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring. Can J Cardiol 2000; 16: 1123-1132.
25. Amerena J, Pappas S, Ouellet J-P, Williams L, O'Shaughnessy D: ABPM comparison of the anti-hypertensive profiles of telmisartan and enalapril in patients with mild-to-moderate essential hypertension. J Int Med Res 2002; 30: 543-552.
26. Lacourcière Y, Tytus R, O'Keefe D, Lenis J, Orchard R, Martin K: Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothicizide in patients uncontrolled with telmisartan monotherapy. J Hum Hypertens 2001; 15: 763-770.
27. McGill JB, Reilly PA: Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension. Clin Cardiol 2001; 24: 66-72.
28. McGill JB, Reilly PA: Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001; 23: 833-850.
29. Lacourcière Y, Martin K: Comparison of a fixed-dose combination of telmisartan 40 mg plus hydrochlorothiazide 12.5 mg with telmisartan 40 mg in the control of mild-to-moderate hypertension. Am J Ther 2002; 9: 111-117.
30. Stangier J, Su CAPF, Schöndorfer G, Roth W: Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. J Clin Pharmacol 2000; 40: 1355-1364.
31. Timmermans PBWM: Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol 1999; 15 (Suppl F): 26F-28F.
32. Wienen W, Entzeroth M, van Meel JCA, Stangier J, Busch U, Ebner T, et al: A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc Drug Rev 2000; 18: 127-156.
33. Stangier J, Su CAPF, Roth W: Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000; 28: 149-167.
34. White WB: Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. Blood Press Monit 2001; 6: 63-72.
35. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, et al: The Seventh Report of the joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
36. Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
37. Garfield FB, Caro JJ: Compliance and hypertension. Curr Hypertens Rep 1999; 1: 502-506.
38. Waeber B, Burnier M, Brunner HR: Compliance with antihypertensive therapy. Clin Exp Hypertens 1999; 21: 973-985.
39. Zyczynski TM, Coyne KS: Hypertension and current issues in compliance and patient outcomes. Curr Hypertens Rep 2000; 2: 510-514.